+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
ID06751901

Personalized Neoantigen Peptide Vaccine Combined With PD-1 Inhibitor and Radiotherapy for Advanced Non-Small Cell Lung Cancer After Second-Line Treatment

Led by The First Affiliated Hospital of Nanchang University · Updated on 2024-12-30

10

Participants Needed

2

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combined treatment approach for patients with advanced non-small cell lung cancer NSCLC that has progressed after second-line treatment. This Phase 2 study aims to assess the safety and effectiveness of a personalized tumor neoantigen-based peptide vaccine, PD-1 inhibitor therapy, and radiotherapy in these patients. The study follows ethical guidelines and includes 10 participants who have experienced disease progression despite prior standard treatments. Participants will receive a personalized radiotherapy course followed by PD-1 inhibitor injections every three weeks. Alongside these treatments, they will get 10 subcutaneous injections of a personalized neoantigen-based peptide vaccine over a 21-week period. The vaccine preparation involves detailed genetic and bioinformatics analysis from blood samples to create tailored peptides that target tumor-specific mutations. This combined treatment plan is designed individually for each patient by their doctor. During the study, participants will undergo regular follow-up visits every six weeks, including blood draws, physical exams, performance assessments, imaging scans CTMRI, X-rays, and laboratory tests. Researchers will monitor the objective response rate, disease control rate, adverse events, progression-free survival, and overall survival. The study duration includes treatment and follow-up, with outcome assessments extending up to approximately 30 weeks for primary measures and up to 66 months for survival outcomes.

CONDITIONS

Brief Title

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

Research Team

Y

Yong Li, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here